A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Sanjay Popat, Alessandra Curioni Fontecedro, Urania G. Dafni et al. · Annals of Oncology · 2020
Cited by 271 works. doi:10.1016/j.annonc.2020.09.009 Open-access PDF
Authors
- Sanjay Popat
- Alessandra Curioni Fontecedro
- Urania G. Dafni
- R. N. Shah
- Mary E.R. O'Brien
- A. Pope
- P.M. Fisher
- James F. Spicer
- A. Roy
- DAVID M. GILLIGAN
- Oliver Pascal Gautschi
- Ernest Nadal
- Wolf-Dieter Janthur
- Rafael López Castro
- Rosario García Campelo
- Sylvie Rusakiewicz
- Igor Letovanec
- Varvara Polydoropoulou
- Heidi Roschitzki‐Voser
- Barbara Ruepp
References
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
- Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline